New weight loss drug candidate shows early promise in stomach study
NCT ID NCT07429032
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called AMG 133 (Maridebart cafraglutide) in 57 adults with overweight or obesity. The goal was to see how the drug affects stomach emptying, using acetaminophen as a marker. Participants received either the drug or a placebo, and researchers measured how quickly the stomach emptied. The study is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMG 133 (Maridebart cafraglutide)
What this could lead to
If successful, this could help develop a new weight management drug that slows stomach emptying, potentially aiding weight loss.
What could go wrong
This is a very early Phase 1 trial with only 57 people, focused on stomach emptying rather than weight loss itself. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117, United States